Predictive biomarkers of benefit to axitinib plus avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC)

被引：0
|
作者：
Hoff, Camilla Oliveira
McGrail, Daniel
Heeke, Simon
de Sousa, Luana Guimaraes
Li, Kaiyi
Bell, Diana
Mitani, Yoshitsugu
Marques-Piubelli, Mario L.
Cortez, Maria Angelica
Lin, Shiaw-Yih
Elamin, Yasir Y.
El-Naggar, Adel K.
Ferrarotto, Renata
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Cleveland Clin, Cleveland, OH USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6096
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A phase 2 study of the oral vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, rivoceranib, for recurrent or metastatic (R/M) adenoid cystic carcinoma (ACC).
    Kang, Hyunseok
    Ahn, Myung-Ju
    Muzaffar, Jameel
    Keam, Bhumsuk
    Bowles, Daniel W.
    Wong, Deborah J. L.
    Ho, Alan Loh
    Kim, Sung-Bae
    Worden, Francis P.
    Yun, Tak
    Sari, Suha
    Conlan, Maureen G.
    Hanna, Glenn J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A phase II study of suberoylanilide hydroxamic acid (SAHA) in subjects with locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC)
    Goncalves, Priscila Hermont
    Kummar, Shivaani
    Siu, Lillian L.
    Hansen, Aaron Richard
    Savvides, Panayiotis
    Sukari, Ammar
    Chao, Joseph
    Heilbrun, Lance K.
    Pilat, Mary Jo
    Smith, Daryn W.
    Casetta, Lindsay
    Boerner, Scott Anthony
    LoRusso, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] A phase II study of lenvatinib in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.
    Tchekmedyian, Vatche
    Sherman, Eric Jeffrey
    Dunn, Lara
    Tran, Crystal
    Katabi, Nora
    Ni, Ai
    Haque, Sofia
    Pfister, David G.
    Ho, Alan Loh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel
    Fukuda, Naoki
    Fujiwara, Yu
    Wang, Xiaofei
    Ohmoto, Akihiro
    Urasaki, Tetsuya
    Hayashi, Naomi
    Sato, Yasuyoshi
    Nakano, Kenji
    Yunokawa, Mayu
    Ono, Makiko
    Tomomatsu, Junichi
    Takahashi, Shunji
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2021, 278 (08) : 3037 - 3043
  • [25] Tumor growth rate as a prognostic factor for metastatic or recurrent adenoid cystic carcinoma of the head and neck patients treated with carboplatin plus paclitaxel
    Naoki Fukuda
    Yu Fujiwara
    Xiaofei Wang
    Akihiro Ohmoto
    Tetsuya Urasaki
    Naomi Hayashi
    Yasuyoshi Sato
    Kenji Nakano
    Mayu Yunokawa
    Makiko Ono
    Junichi Tomomatsu
    Shunji Takahashi
    European Archives of Oto-Rhino-Laryngology, 2021, 278 : 3037 - 3043
  • [26] ACCURACY: phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notchact mut).
    Ferrarotto, Renata
    Ho, Alan Loh
    Wirth, Lori J.
    Dekel, Edith
    Walker, Russell W.
    Vergara-Silva, Andrea Leninka
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC
    Chau, N. G.
    Hotte, S. J.
    Chen, E. X.
    Chin, S. F.
    Turner, S.
    Wang, L.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1562 - 1570
  • [28] Successful treatment of c-kit-positive metastatic Adenoid Cystic Carcinoma (ACC) with a combination of curcumin plus imatinib: A case report
    Demiray, M.
    Sahinbas, H.
    Atahan, S.
    Demiray, H.
    Selcuk, D.
    Yildirim, I.
    Atayoglu, A. T.
    COMPLEMENTARY THERAPIES IN MEDICINE, 2016, 27 : 108 - 113
  • [29] ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)
    Ferrarotto, R.
    Wirth, L. J.
    Muzaffar, J.
    Rodriguez, C. P.
    Xia, B.
    Perez, C. A.
    Bowles, D. W.
    Winquist, E.
    Hotte, S. J.
    Metcalf, R.
    Even, C.
    Gordon, G. B.
    Gordon, G.
    Ho, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S663 - S663
  • [30] A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
    Mahmood, Umair
    Bang, Andrew
    Chen, Yu-Hui
    Mak, Raymond H.
    Lorch, Jochen H.
    Hanna, Glenn J.
    Nishino, Mizuki
    Manuszak, Claire
    Thrash, Emily M.
    Severgnini, Mariano
    Sanborn, Matthew
    Sridharan, Vishwajith
    Margalit, Danielle N.
    Tishler, Roy B.
    Busse, Paul M.
    Willers, Henning
    Mamon, Harvey J.
    Yoo, Hyung-Jin
    Pai, Sara, I
    Wirth, Lori J.
    Haddad, Robert, I
    Chau, Nicole G.
    Schoenfeld, Jonathan D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 109 (01): : 134 - 144
12345